|  |  |  | | | | | TE-RegenMed-StemCell feed | | | | | | | | | | | | | | | | | | The $3 billion California stem cell agency has done an "extraordinary" job so far, a blue-ribbon review panel said today, and should expand its efforts internationally, create closer ties with the biotech industry and perform triage on its existing portfolio of research grants.
The panel's 19-page report said that the agency now stands at a critical point as its first and only chairman, Robert | | | | | | | | | | | | | | | | | | | | | | | | Here is a list of the recommendations of the blue-ribbon panel concerning the California stem cell agency.
• Build on CIRM's previous and ongoing investments
• Sharpen the focus on meaningful, targeted excellence required for global leadership in
the development of innovative treatments based on regenerative medicine
• Sustain a vigorous program of fundamental discovery while, at the same time, | | | | | | | | | | | | | | | | | | | | | | | | | The 19-page report from the blue-ribbon panel that reviewed the operations of the California stem cell agency is now available. We will have an item on the report, plus excerpts, a little later this afternoon. | | | | | | | | | | | | | | | | | | | | | | | | Only four business days remain before a key California stem cell agency meeting that will deal with its financial future and the future of its departing chairman, Robert Klein, but the $3 billion state enterprise still is not providing any information to the public on those matters beyond cryptic hints.
The failure to provide the information represents a continuing and inexplicable problem with | | | | | | | | | |  | |  | |  |
No comments:
Post a Comment